TIME magazine has named women's health specialist Sprout Pharmaceuticals among 10 organisations globally shaping the future of health and life sciences.
This recognition follows a defining period of momentum for Sprout and its flagship treatment, Addyi.
In December 2025, the US Food and Drug Administration (FDA) approved an expanded indication for Addyi to include all women under 65 with Hypoactive Sexual Desire Disorder (HSDD), regardless of menopausal status, unlocking a significantly broader patient population and accelerating commercial expansion.
TIME evaluated companies based on impact, innovation, ambition, and success, selecting just 10 companies in health and life sciences as industry leaders.
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19
FDA grants rare paediatric disease designation to RedHill's opaganib
GSK to acquire Nuvalent for USD10.6bn to expand lung cancer portfolio
Galmed Pharmaceuticals to acquire Colospan for GI-focused platform development
Alvotech reports FDA review acceptance for Entyvio biosimilar candidate AVT16
Sanofi secures EU approval for subcutaneous Sarclisa with on-body injector
Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline
Lupin's Ranluspec (ranibizumab) injection receives US FDA approval
Pharming secures FDA acceptance of Joenja filing for children with APDS
Medtronic seeks expanded US approvals for Hugo robotic surgery system
MiniMed expands Abbott partnership for dual glucose-ketone diabetes sensors
Lupin and Natco secure US FDA approval for generic Eribulin Mesylate Injection
Luminopia agrees international licensing deal for paediatric amblyopia treatment in Japan